Abstract:e13606 Background: Sunitinib is considered the first-line therapy for advanced clear cell renal cell carcinoma (ccRCC). However, a complete understanding of its targets and mechanism of action and resistance in ccRCC remains incomplete. The aim of this study was to evaluate the mechanism action of sunitinib and its resistance in RCC and to identify potential targets to overcome sunitinib resistance. Methods: Western blotting of ccRCC and endothelial cell lines confirmed that PDGFR and VEGFR, but not other sunitinib targets, were expressed in these cells. In vitro studies found that sunitinib was unable to inhibit survival or proliferation of ccRCC cells at pharmacologically relevant concentrations (∼0.1 μM) which inhibit RTK targets. In contrast, sunitinib inhibited endothelial cell proliferation and invasion at these concentrations through suppression of VEGFR-2 signaling. Sunitinib inhibited growth of ccRCC xenografts and decreased tumor microvessel density as soon as 12 hours post-treatment; however, sunitinib showed no significant effects on tumor cell proliferation or apoptosis after up to 72 hours post-treatment. Results: Our studies indicate that sunitinib inhibits ccRCC growth primarily through an anti-angiogenic mechanism and not through direct targeting of ccRCC tumor cells. Higher microvessel density was found in sunitinib-resistant tumors, which indicated that an escape from anti-angiogenesis occurred in these tumors. This escape coincided with increased tumor secretion of interleukin-8 (IL-8) into the plasma. Co-administration of an IL-8 neutralizing antibody resensitized these tumors to sunitinib treatment, demonstrating the functional contribution of IL-8 to sunitinib resistance. Immunohistochemical staining showed that IL-8 expression was elevated in ccRCC tumors from patients who were refractory to sunitinib treatment, indicating IL-8 levels may predict clinical response to sunitinib. Conclusions: In conclusion, our results demonstrate that IL-8 is an important contributor, among others, to sunitinib resistance in ccRCC. IL-8 may serve as a therapeutic target for treatment of sunitinib resistant ccRCC, as well as a biomarker for both acquired and intrinsic sunitinib resistance. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Global Pharmaceuticals

Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

Mir-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Elucidating Mechanisms of Sunitinib Resistance in Renal Cancer: an Integrated Pathological-Molecular Analysis.

Candidate Gene and MicroRNA Biomarkers of Metastatic Renal Cell Carcinoma (MRCC) Response to Sunitinib

Key sunitinib-related biomarkers for renal cell carcinoma

Overexpression of Mir-15B Promotes Resistance to Sunitinib in Renal Cell Carcinoma

Circulating Cytokines and Monocyte Subpopulations As Biomarkers of Outcome and Biological Activity in Sunitinib-Treated Patients with Advanced Neuroendocrine Tumours

Circular RNA Circagap1 Promotes Sunitinib Sensitivity in Renal Cell Carcinoma Via Sponging Multiple PDGFR-targeted Mirnas

Mir-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor

Gene expression profile of renal cell carcinomas after neoadjuvant treatment with sunitinib: new pathways revealed

Sunitinib Induces Early Histomolecular Changes in a Subset of Renal Cancer Cells That Contribute to Resistance.

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles

LINC00160 Mediates Sunitinib Resistance Via SAA1/STAT3 Signaling Pathways and ABCB1 Transmembrane Transport in Renal Cell Carcinoma

Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

The Mechanism Of Action And Resistance Of Sunitinib In Rcc.

Exploring the tumor microenvironment: Chemokine‐related genes and immunotherapy/chemotherapy response in clear‐cell renal cell carcinoma

A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.

Correction To: Sunitinib-suppressed Mir-452-5p Facilitates Renal Cancer Cell Invasion and Metastasis Through Modulating SMAD4/SMAD7 Signals